Financial comparisons Charles River Laboratories International, Inc. Berne S.E.
Stocks
RV6
US1598641074
Biotechnology & Medical Research
|
End-of-day quote
Berne S.E.
04/09/2026
|
5-day change | 1st Jan Change | ||
| 234.24 CHF | +0.11% |
|
-1.18% | - |
| 21/08 | Charles River Laboratories International Insider Sold Shares Worth $599,711, According to a Recent SEC Filing | MT |
| 20/08 | Charles River, Medigen Partner on Multivalent Enterovirus Vaccine | MT |
Main competitors
| Revenues (Y-1) | Net Margin (Y-1) | EBIT Margin (Y-1) | ROE (Y-1) | ROA (Y-1) | Leverage (Y-1) | ||
|---|---|---|---|---|---|---|---|
 | 823.63Cr | 14.53% | 21.7% | 10.28% | 4.9% | 1.58x | |
| 1.63TCr | 8.34% | 13.38% | 32.9% | 4.79% | 3.63x | |
| 534.3Cr | 5.37% | 8.37% | 29.84% | 16.27% | -5.99x | |
| 288.36Cr | 24.74% | 28.07% | 5.94% | 4.75% | 1.77x | |
| 85Cr | -31.67% | -18.92% | - | - | 1.57x | |
| 253.02Cr | 17.83% | 20.93% | 70.23% | 22.13% | -0.89x | |
| 856.64Cr | 6.51% | 14.79% | 9.61% | 4.34% | 2.22x | |
| 401.54Cr | -3.59% | 19.77% | 15.46% | 6.99% | 1.98x | |
| 825.13Cr | 2.78% | 16.66% | 10.62% | 6.02% | 1.8x | |
| 127.18Cr | -19.27% | -3.71% | -38.64% | -6.61% | -65.61x | |
| 121.5Cr | 14.97% | 31.77% | 15.06% | 11.79% | -0.15x | |
| 54.01L | -7,306.52% | -5,350% | -135.58% | - | 2.1x | |
| 201.52Cr | 11.8% | 13.68% | 11.6% | 6.52% | 1.83x | |
| 3.92Cr | -794.04% | -891.07% | -25.78% | -22.89% | 4.75x | |
| 94Cr | -40.36% | -40.47% | -70.72% | -11.67% | 4.51x | |
| 4.6Cr | -282.83% | -343.63% | -20.18% | -18.42% | 0.82x | |
| 209Cr | 20.33% | 29.46% | 17.5% | 10.73% | 0.74x | |
| Average | 380.05Cr | -491.24% | -378.19% | -3.86% | 2.64% | -2.55x | |
| Weighted average by Cap. | 572.25Cr | -265.45% | -199.46% | 7.99% | 5.35% | -1.46x |
- Stock Market
- Stocks
- CRL Stock
- RV6 Stock
- Sector Charles River Laboratories International, Inc.
- Financial comparisons
Select your edition
All financial news and data tailored to specific country editions
